Literature DB >> 29945115

The down-regulation of microRNA-137 contributes to the up-regulation of retinoblastoma cell proliferation and invasion by regulating COX-2/PGE2 signaling.

Jian Zhang1, Jing He2, Le Zhang1.   

Abstract

MicroRNA-137 (miR-137) plays an important role in the development and progression of many types of human cancers; however, the role of miR-137 in retinoblastoma (RB) remains unclear. In this study, we aimed to investigate the functional significance and molecular mechanisms of miR-137 in RB. We reported that miR-137 was frequently down-regulated in RB tissues and cell lines. The overexpression of miR-137 inhibited RB cell proliferation and invasion, while the suppression of miR-137 promoted RB cell proliferation and invasion. Bioinformatic analysis predicted that cyclooxygenase-2 (COX-2) was a potential target gene of miR-137, which was validated by a dual-luciferase reporter assay. Moreover, our results showed that miR-137 negatively regulated the expression of COX-2 and the production of prostaglandin E2 (PGE2) in RB cells. The knockdown of COX-2 suppressed the proliferation and invasion of RB cells as well as the production of PGE2. The overexpression of COX-2 significantly reversed the inhibitory effect of miR-137 overexpression on RB cell proliferation and invasion. Taken together, these results suggest that miR-137 suppresses the proliferation and invasion of RB cells by targeting COX-2/PGE2. Our study reveals a tumor suppressive role of miR-137 in the progression of RB and suggests miR-137 as a potentially effective therapeutic target for the treatment of RB.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  COX-2; PGE2; Retinoblastoma; miR-137

Mesh:

Substances:

Year:  2018        PMID: 29945115     DOI: 10.1016/j.biopha.2018.06.099

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

1.  MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.

Authors:  Yang Cheng; Wei Liu
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

Review 2.  Expression profiles and prognostic value of miRNAs in retinoblastoma.

Authors:  Lara Elis Alberici Delsin; Karina Bezerra Salomao; Julia Alejandra Pezuk; Maria Sol Brassesco
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-22       Impact factor: 4.553

3.  Interplay between cyclooxygenase‑2 and microRNAs in cancer (Review).

Authors:  Zexiong Gong; Weiguo Huang; Baiyun Wang; Na Liang; Songkai Long; Wanjun Li; Qier Zhou
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

Review 4.  MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer.

Authors:  Lu Zhang; Yi Liao; Liling Tang
Journal:  J Exp Clin Cancer Res       Date:  2019-02-04

Review 5.  MitomiRs: their roles in mitochondria and importance in cancer cell metabolism.

Authors:  Andrej Rencelj; Nada Gvozdenovic; Maja Cemazar
Journal:  Radiol Oncol       Date:  2021-11-19       Impact factor: 2.991

6.  MiR-1301-3p Inhibits Epithelial-Mesenchymal Transition via Targeting RhoA in Pancreatic Cancer.

Authors:  Xinxue Zhang; Zhangyong Ren; Junming Xu; Qing Chen; Jun Ma; Zhe Liu; Jiantao Kou; Xin Zhao; Ren Lang; Qiang He
Journal:  J Oncol       Date:  2022-02-26       Impact factor: 4.375

Review 7.  Epigenetic strategies to boost CAR T cell therapy.

Authors:  Behnia Akbari; Navid Ghahri-Saremi; Tahereh Soltantoyeh; Jamshid Hadjati; Saba Ghassemi; Hamid Reza Mirzaei
Journal:  Mol Ther       Date:  2021-08-06       Impact factor: 12.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.